The experimental cream can make a “permanent” scars from the past

Great men may have scars, but many people will enjoy the opportunity to get rid of themselves. In a new research this week, a experimental drug showed a promise to clarify the remaining scars.

Scientists in Australia conducted the study, which is the first stage of tropical cream developed by Syntara. They have found people who apply the cream any major side effects, and the drug appears to be raising changes in the skin inside the old or mature scars. The researchers say that although these results are still early, they may indicate a possible treatment for permanent scars otherwise.

Why is the scars very troublesome

Our skin tends to heal easily from minor wounds and without permanent defects, but larger or deeper injuries often lead to the formation of a scar tissue. Most scars fade over time and become less clear, but they rarely disappear completely. Wide scars can significantly change our appearance or Even an obstacle The movement of the joints and nearby muscles.

Although interventions such as surgery or laser treatment can improve the appearance of scars, scientists are still trying to find less interventions that can prevent or wipe the tissue of the scar.

SYNTARA (previously known as Pharmaxis) was Growth Drugs bearing the name SNT-6302 to treat a scar. It aims to work by inhibiting enzymes known as oxidise lesel. These enzymes encourage the production of “cross -links” linking collagen threads tightly. Although the iconic oxids usually helps to maintain the health of our skin and sound, excess production helps to cause severe and durable scar tissue. So by inhibiting the production of these enzymes in scar tissue with medications such as SNT-6302, hope is to encourage the right skin’s return.

An early promise

The researchers at Fiona Stanley and Western University of Australia helped in test SNT-6302 in a small experience of 50 volunteers, all of whom have mature scars (a mature scar when they are fully installed and are no longer inflamed or itching).

Eight Volunteers SNT-6302 were given to take it daily, while the rest was randomly assigned to receive the medicine or a delicious medicine cream. Those in the random group apply treatment to their scars three times a week for three months.

The first stage experiences aim in the first place to test the safety of the drug or the experimental vaccine, and the SNT-6302 appears to meet this standard. The only negative events that were reported were light treatment to moderate local skin reactions, although six participants had stopped it as a result. The drug also appears to show some initial signs of work as required.

In the treatment group, the drug is reduced from Oxidise Lesel activity by 66 %, and it appears to reduce collagen production and total protein. Imaging tests also found that the SNT-6302 increased the density of microscopic blood vessels, indicating the redesign of the skin for a more unlike tissue.

Team results, Published Thursday in Scientific Medicine for Science, is still primary. The researchers wrote that the results of safety, the success of the successful leesydis oxidis, and the early signs of the reinterprection of the skin provide support for the larger and longer periods of SNT-6302, as the researchers wrote.

Here in the hope that the medicine will continue to work as expected, and I can finally erase my embarrassing reminders at the time I tried to ride a bike while eating a hot dog when I was five years old.